Deciphera Pharmaceuticals, Inc. (NASDAQ: DCPH), a biopharmaceutical company focused on discovering, developing, and commercializing important new medicines to improve the lives of people with cancer, ...

OSAKA, Japan & WALTHAM, Mass.--(BUSINESS WIRE)--Ono Pharmaceutical, Co., Ltd. (Headquarters: Osaka, Japan; President: Toichi Takino; “Ono”) today announced that the U.S. Food and Drug Administration ...

The trial is enrolling in the US and will include regions in the Asia Pacific, Europe, Latin America, and North America.

On Monday, Japanese pharma company ONO Pharmaceutical agreed to acquire Deciphera Pharmaceuticals Inc (NASDAQ:DCPH) for $25.60 per share in cash, for a total equity value of $2.4 billion. Deciphera ...

The above button links to Coinbase. Yahoo Finance is not a broker-dealer or investment adviser and does not offer securities or cryptocurrencies for sale or facilitate trading. Coinbase pays us for ...

Ono Pharmaceutical has agreed to buy cancer drugmaker Deciphera Pharmaceuticals in a deal that values the latter company at $2.4 billion. Per deal terms, Ono is purchasing in cash all outstanding ...

MBX Biosciences appointed Steve Hoerter chairman and chief executive, effective immediately, succeeding Kent Hawryluk. Hoerter has served as executive chairman since November 2025 and joined the board ...

Deciphera Pharmaceuticals, Inc. DCPH announced that it has dosed the first patient in a phase I study which is evaluating its investigational ULK kinase inhibitor, DCC-3116, for the treatment of ...

Deciphera Pharmaceuticals Inc DCPH announced top-line results from the MOTION Phase 3 study of vimseltinib in patients with Tenosynovial Giant Cell Tumor (TGCT) not amenable to surgery. The study met ...

The company reported $42.1 million in revenue for 2020, up from $25 million in 2019. Qinlock (ripretinib) was responsible for most of that revenue, including $38 million in the U.S. and $1.5 million ...